Table 2.
Stepwise Model of Genetic Factors Associated with Drusen Size Progression
| Drusen Size Progression | ||
|---|---|---|
| HR (95% CI)* | P Value | |
| Complement pathway | ||
| CFH Y402H: rs1061170 | 1.22 (1.02–1.43) | 0.03 |
| CFH: rs1410996 | 1.22 (1.01–1.48) | 0.04 |
| CFH R1210C: rs121913059 | 5.85 (2.44–14.06) | <0.001 |
| C2 E318D: rs9332739 | 0.44 (0.28–0.69) | <0.001 |
| C3 R102G: rs2230199 | 1.45 (1.26–1.67) | <0.001 |
| C3 K155Q: rs147859257 | 2.19 (0.98–4.88) | 0.05 |
| Angiogenesis pathway | ||
| VEGFA: rs943080 | 1.19 (1.04–1.36) | 0.01 |
| Immune inflammatory pathway | ||
| ARMS2/HTRA1 A69S: rs10490924 | 1.34 (1.17–1.54) | <0.001 |
| Extracellular matrix | ||
| TIMP3: rs9621532 | 1.52 (1.16–2.01) | 0.003 |
| DNA repair/protein binding | ||
| NPLOC4/TSPAN10: rs9895741 | 1.16 (1.02–1.32) | 0.02 |
| HSPH1/B3GALTL: rs9542236 | 1.21 (1.06–1.39) | 0.005 |
*
HRs for drusen size progression represent risk per allele, and are adjusted for age, sex, education, smoking, BMI, drusen size grade at baseline, AREDS treatment, multivitamin supplement use. Eyes were used as the unit of analysis.